Providence Therapeutics Press Releases - Providence Therapeutics

BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2021 Achievement Awards Ceremony, Sir Michael Houghton Inducted Into Alberta Bioindustry Hall of Fame

Written on March 30, 2022

Providence Therapeutics and Everest Medicines announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program

Written on December 20, 2021

Providence Therapeutics Holdings Inc., VaxThera S.A.S, and the Ministry of Health and Social Protection of the Republic of Colombia, announce the signing of an MOU to explore collaborations for COVID-19 vaccine development

Written on December 17, 2021

Providence Therapeutics announces $ 2.118 Million USD in funding to support process development and validation of the PTX-COVID19-B program, which targets high quality mRNA COVID-19 vaccine to low-to middle-income countries at affordable prices.

Written on December 07, 2021

Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

Written on December 01, 2021

Providence Therapeutics Announces Donna T. Ward, Ph.D., J.D. appointment to Board of Directors

Written on October 28, 2021

Northern RNA and Providence Therapeutics Announce Multi-year Agreement to Provide Essential Raw Materials and GMP Manufacturing in Support of Providence Therapeutics mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Written on September 14, 2021

Emergent Biosolutions Secures Multi-year Development and Manufacturing Agreement With Providence Therapeutics for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Written on September 14, 2021

Providence Therapeutics Enters into Comprehensive Agreements with Everest Medicines to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Emerging Markets in Asia

Written on September 13, 2021

Providence Therapeutics Reports PTX-COVID19-B, its mRNA Vaccine for COVID-19, Neutralizes SARS-CoV-2 and Variants of Concern, Including Delta

Written on September 13, 2021

Providence Therapeutics Holdings Inc. Of Canada and Biological E. Limited of India Announce the Execution of a Term Sheet for the Licensing and Collaboration of mRNA Vaccine

Written on June 01, 2021

Providence Therapeutics Announces Very Favorable Interim Phase 1 Trial Data for PTX-COVID19-B, its mRNA Vaccine Against COVID-19

Written on May 12, 2021

Providence Therapeutics Announces First Subject Has Been Dosed in Covid-19 Vaccine Trial

Written on January 26, 2021

Providence Therapeutics Announces New Chief Development Officer and Chief Medical Officer

Written on January 22, 2021

Providence Therapeutics COVID-19 Vaccine Receives Health Canada Authorization to Begin Clinical Trials

Written on December 23, 2020

Providence Therapeutics Submits Clinical Trial Application (CTA) to Health Canada for its mRNA COVID Vaccine

Written on December 04, 2020

Providence Therapeutics Announces Jared Davis as President

Written on December 01, 2020

Providence Therapeutics Reports Supportive Preclinical Data for its COVID-19 Vaccine Candidate (PTX-COVID19-B)

Written on August 05, 2020

Press
Releases